News

Biologics Increase Risk of Postoperative Infection


 

SAN ANTONIO β€” Rheumatoid arthritis patients who are on tumor necrosis factor-inhibitor therapy have a fourfold greater risk of developing deep postoperative infections, according to a Johns Hopkins University review of patients who had undergone orthopedic procedures.

The findings, although not definitive, suggest that these agents should be stopped before surgery, Jon T. Giles, M.D., said at the annual meeting of the American College of Rheumatology.

Based on each agent's half-life, Dr. Giles recommended that etanercept be discontinued 2 weeks before surgery, infliximab 8 weeks before surgery, and adalimumab 4 weeks before surgery.

β€œIn addition, we recommend avoidance of TNF inhibitors for 2 weeks after surgery,” he said.

Even without adding the biologics, patients with rheumatoid arthritis already have a higher risk of postoperative infection, noted Dr. Giles of Johns Hopkins University, Baltimore. Compared with a 1% rate of infection among people in the general population undergoing orthopedic procedures, infection rates among rheumatoid arthritis patients are two- to fourfold higher.

Dr. Giles's investigation involved 91 RA patients who had undergone a bone or joint surgical procedure in a Johns Hopkins clinic during a 5-year period from the beginning of 1999. Half of those patients had large joint arthroplasty procedures, and the rest were divided between fusion or resection procedures with no implanted materials and small joint procedures.

Among the 35 patients identified to be on biologic therapy at the time of surgery, seven developed early, deep, postoperative infections, including two cases of osteomyelitis, three cases of septic arthritis, and two cases of paraspinal abscess. There were three infections among the 56 patients not taking a biologic.

Patients on TNF-inhibitor therapy had an unadjusted 4.4 odds ratio for developing infection, compared with those patients not on the biologics; after adjustments for age, gender, and disease duration, the odds ratio rose to 4.6. After adjustment for prednisone use, diabetes, and presence of rheumatoid factor, the odds ratio was 5.3.

Given the study's small numbers, it could not be determined if the risk of infection varied by the type of surgery, site of surgery, or particular biologic agent used.

Recommended Reading

Standard-Dose Infliximab Tied to Few Infections
MDedge Rheumatology
Low-Dose Steroids' Safety Wrongly Disparaged
MDedge Rheumatology
Chloroquine May Alter CVD Risk in RA Patients
MDedge Rheumatology
Acetaminophen's Role in OA Upheld by New Data
MDedge Rheumatology
Rose Hip Reduces OA Hand Pain and Stiffness
MDedge Rheumatology
Simple Trapeziectomy Sufficient For Thumb Osteoarthritis
MDedge Rheumatology
Seven Years of Follow-Up Data Available on Etanercept
MDedge Rheumatology
Preliminary Data Mixed on IL-15 as RA Target
MDedge Rheumatology